Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
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
UTTuefw9C31XR491
